Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAGM Regimen in R/R DLBCL
NCT05823701Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and azacitidine in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Overall Response Rate at Cycle 2 and Complete Response Rate at Cycle 2. Started Sep 2022; status: recruiting.
02
Drugs
tucidinostatazacitidine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05823701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05823701.